hu-210 and Inflammation

hu-210 has been researched along with Inflammation* in 2 studies

Other Studies

2 other study(ies) available for hu-210 and Inflammation

Article	Year
Pyridine-3-carboxamides as novel CB(2) agonists for analgesia. Bioorganic & medicinal chemistry letters, 2009, Jan-01, Volume: 19, Issue:1 We describe herein the medicinal chemistry approach which led to the discovery of a novel pyridine-3-carboxamide series of CB(2) receptor agonists. The SAR of this new template was evaluated and culminated in the identification of analogue 14a which demonstrated efficacy in an in vivo model of inflammatory pain. Topics: Amides; Analgesia; Analgesics; Animals; Disease Models, Animal; Drug Discovery; Inflammation; Pain; Pyridines; Receptor, Cannabinoid, CB2; Structure-Activity Relationship	2009
Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. Journal of medicinal chemistry, 2007, May-31, Volume: 50, Issue:11 Selective CB2 receptor agonists are promising potential therapeutic agents for the treatment of inflammatory and neuropathic pain. A focused screen identified a pyrimidine ester as a partial agonist at the CB2 receptor with micromolar potency. Subsequent lead optimization identified 35, GW842166X, as the optimal compound in the series. 35 has an oral ED50 of 0.1 mg/kg in the rat FCA model of inflammatory pain and was selected as a clinical candidate for this indication. Topics: Analgesics; Animals; Biological Availability; Half-Life; Humans; Inflammation; Pain; Pyrans; Pyrimidines; Rats; Receptor, Cannabinoid, CB2; Structure-Activity Relationship	2007

Article

Year

Pyridine-3-carboxamides as novel CB(2) agonists for analgesia.

Bioorganic & medicinal chemistry letters, 2009, Jan-01, Volume: 19, Issue:1

We describe herein the medicinal chemistry approach which led to the discovery of a novel pyridine-3-carboxamide series of CB(2) receptor agonists. The SAR of this new template was evaluated and culminated in the identification of analogue 14a which demonstrated efficacy in an in vivo model of inflammatory pain.

Topics: Amides; Analgesia; Analgesics; Animals; Disease Models, Animal; Drug Discovery; Inflammation; Pain; Pyridines; Receptor, Cannabinoid, CB2; Structure-Activity Relationship

2009

Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain.

Journal of medicinal chemistry, 2007, May-31, Volume: 50, Issue:11

Selective CB2 receptor agonists are promising potential therapeutic agents for the treatment of inflammatory and neuropathic pain. A focused screen identified a pyrimidine ester as a partial agonist at the CB2 receptor with micromolar potency. Subsequent lead optimization identified 35, GW842166X, as the optimal compound in the series. 35 has an oral ED50 of 0.1 mg/kg in the rat FCA model of inflammatory pain and was selected as a clinical candidate for this indication.

Topics: Analgesics; Animals; Biological Availability; Half-Life; Humans; Inflammation; Pain; Pyrans; Pyrimidines; Rats; Receptor, Cannabinoid, CB2; Structure-Activity Relationship

2007